pneumonia%20-%20community-acquired
PNEUMONIA - COMMUNITY-ACQUIRED
Community-Acquired Pneumonia (CAP) is an acute infection of the pulmonary parenchyma accompanied by symptoms of acute illness and abnormal chest findings.
It is a lower respiratory tract infection acquired in the community within 24 hours to <2 weeks or occurring ≤48 hours of hospital admission in patients who do not meet the criteria for healthcare-associated pneumonia.
It occurs at the highest rates in the very young and the very old.
Potentially life-threatening especially in older adults and those with comorbid disease.

Principles of Therapy

  • Antibiotics should be initiated as soon as possible upon the diagnosis of community-acquired pneumonia (CAP)
  • Consider local antimicrobial resistance patterns when choosing an antibiotic
  • Among patients with recent antibiotic exposure, do not use antibiotics in the same class as the patient had been receiving previously
  • Infection with anaerobes should also be considered as possible causative organisms in patients with risk of aspiration
  • In patients with low severity, consider a 5-day single antibiotic course
    • May extend duration if patient is still symptomatic after 3 days of treatment
    • Dual antibiotic therapy & quinolones should be avoided in low-severity patients
  • In patients with moderate-high severity, a 7-10-day antibiotic course is recommended
    • Dual antibiotic therapy (Amoxicillin plus a macrolide) is recommended for patients with moderate severity CAP
    • Dual antibiotic therapy with a beta-lactamase stable beta-lactam plus a macrolide is recommended for high severity CAP patients
  • In patients with high-risk pneumonia, the parenteral route is recommended for all antimicrobial administration because the severity of the condition may result in a low perfusion state

Pharmacotherapy

Recommended Empiric Antibiotic Therapy
Potential Pathogens Patient Condition Antibiotic
Low-risk Pneumonia
Streptococcus pneumoniae
Haemophilus influenzae
Chlamydophilia pneumoniae Mycoplasma pneumoniae
Moraxella catarrhalis
Enteric Gram-negative bacilli (among those with comorbid illnesses)
Previously healthy

Amoxicillin or
Extended macrolides1 (Azithromycin or Clarithromycin)

  • If with high rates of macrolide-resistant S pneumoniae, consider recommendations below for patients with stable comorbid illness
With stable comorbid illness Beta-lactam or beta-lactamase inhibitor combination (BLIC)² or 2nd generation cephalosporins³ with or without extended macrolides1
Co-amoxiclav or Sultamicillin or  Cefuroxime axetil with or without Azithromycin or Clarithromycin
Moderate-risk Pneumonia
S pneumoniae
H influenzae
C pneumoniae
M pneumoniae
M catarrhalis

Enteric Gram-negative bacilli
L pneumophila
Anaerobes (in patients with risk of aspiration)
- Non-antipseudomonal beta-lactam (BLIC, Cephalosporins) intravenous2 (IV) plus
Extended macrolides1 or respiratory fluoroquinolones6

Ampicillin-Sulbactam or
Cefuroxime or Ceftriaxone plus
Azithromycin or Clarithromycin or Levofloxacin or Moxifloxacin

  • If there is a suspicion of aspiration pneumonia and Ampicillin-Sulbactam and/or Moxifloxacin was used, adding of another antibiotic for an additional anaerobic coverage is not needed
  • May add Clindamycin to the regimen if another combination is used to cover for microaerophilic streptococci
High-risk Pneumonia
S pneumoniae
H influenzae
C pneumoniae
M pneumoniae
M catarrhalis

Enteric Gram-negative bacilli
L pneumophila
Anaerobes (among those w/ risk of aspiration)
Staphylococcus aureus
Pseudomonas aeruginosa
No risk for P aeruginosa Non-antipseudomonal beta-lactam IV4  plus
Extended macrolides IV1 or
Respiratory fluoroquinolones IV6
Ceftriaxone or Ertapenem IV plus
Azithromycin IV or Levofloxacin IV or Moxifloxacin IV
W/ risk for P aeruginosa Antipneumococcal antipseudomonal beta-lactam (BLIC, Cephalosporins, or Carbapenem) IV5 plus
Extended macrolides IV¹ plus 
Aminoglycoside
Piperacillin-Tazobactam or Cefepime or Meropenem plus 
Azithromycin plus 
Gentamicin or Amikacin
Antipneumococcal antipseudomonal beta-lactam (BLIC, Cephalosporins, or Carbapenem) IV5 plus
Ciprofloxacin or high dose Levofloxacin IV
 Piperacillin-Tazobactam or Cefepime or Meropenem plus
Levofloxacin or Ciprofloxacin
 Is MRSA pneumonia is suspected, add:  Vancomycin or Linezolid or Clindamycin

¹Extended macrolides: Azithromycin & Clarithromycin
²Oral beta-lactam or beta-lactamase inhibitor combination (BLIC): Amoxicillin-Clavulanic acid, Sultamicillin
³Oral second-generation Cephalosporins: Cefuroxime axetil
4Non-antipseudomonal beta-lactam (BLIC, Cephalosporins or Carbapenem) IV: Ampicillin-Sulbactam, Cefuroxime Na, Ceftriaxone, Ertapenem
5Antipneumococcal, antipseudomonal beta-lactam (BLIC, Cephalosporins or Carbapenem) IV: Piperacillin-Tazobactam, Cefepime, Imipenem-Cilastatin, Meropenem
6Respiratory fluoroquinolones: Levofloxacin, Moxifloxacin

Beta-Lactams

Low-Risk Pneumonia

  • High-dose Amoxicillin or Co-amoxiclav is preferred
    • Targets >93% of S pneumoniae
    • Comorbidities or recent antimicrobial therapy increase the likelihood of infection with drug-resistant S pneumonia and enteric Gram-negative bacteria which may be treated using a combination of a beta-lactam and a macrolide
  • 2nd generation cephalosporins can be used as an alternative antibiotic therapy for patients with stable co-morbid conditions
  • Less active in vitro than high-dose Amoxicillin

Moderate-Risk and High-Risk Pneumonia

  • Parenteral nonpseudomonal beta-lactams with or without a beta-lactamase inhibitor are recommended; some antibiotics from this class may also have anaerobic activity
    • May be given with either an extended macrolide or a respiratory quinolone
  • Recommended beta-lactams include penicillins, 2nd- and 3rd-generation cephalosporins and carbapenems
  • Combining nonpseudomonal beta-lactams with macrolides results in a significant reduction in mortality
  • Oxacillin
    • Consider giving to patients shown or suspected to have lung abscesses, pneumatoceles or pyothorax, in which Staphylococcus sp is a common etiologic organism
    • The best indicator of S aureus infection is the presence of Gram-positive cocci in clusters in a tracheal aspirate or in an adequate sputum sample

Macrolides

Low-Risk Pneumonia

  • Macrolides and azalides may be better for patients with extrapulmonary physical findings, a feature of pneumonia caused by atypical pathogens
  • Alternative for patients who are hypersensitive to Penicillin
  • Erythromycin is less active against H influenzae
  • Azithromycin is preferred for outpatients with comorbidities (eg COPD) because of H influenzae

Moderate-Risk and High-Risk Pneumonia

  • Combining macrolides with nonpseudomonal beta-lactams results in reduced mortality
  • Adding a macrolide to the antibiotic regimen benefits patients in areas with a high prevalence of Legionella sp

Quinolones with Anti-Pneumococcal Action (Respiratory Quinolones)

Low-Risk Pneumonia

  • Recommended for those with comorbid illnesses or recent antibiotic treatment which increase the chance of infection with resistant S pneumoniae or enteric Gram-negative bacilli

Moderate-Risk Pneumonia

  • May be used alone as an alternative regimen to nonpseudomonal beta-lactam with or without beta-lactamase inhibitor plus a macrolide
  • In areas with high prevalence of pulmonary tuberculosis (TB), they are better reserved as potential 2nd-line agents for the treatment of multidrug-resistant TB
    • Quinolones may mask the clinical features of pulmonary TB and delay its diagnosis

Clindamycin, Metronidazole

Moderate-Risk Pneumonia

  • Add Clindamycin or Metronidazole to the antibiotic regimen in patients with suspected aspiration

Duration of Treatment Based on Etiology

Low-Risk Pneumonia

  • Minimum of 5 days; usual duration is 5-7 days for most pneumonias of bacterial etiology
  • A 3-day course of oral therapy may be possible with azalides

Moderate-Risk And High-Risk Pneumonia

Etiologic Agent Duration of Therapy
  • Most bacterial pneumonias except enteric Gram-negative pathogens (MRSA and MSSA), and P aeruginosa
5-7 days; 3-5 days (azalides) for S pneumoniae
  • Enteric Gram-positive pathogens, S aureus (MRSA and MSSA) & P aeruginosa

MSSA CAP

  • Non-bacteremic - 7-14 days
  • Bacteremic - longer; up to 21 days

MRSA CAP

  • Non-bacteremic -  7-21 days
  • Bacteremic - longer; up to 28 days

P aeruginosa

  • Non-bacteremic - 14-21 days
  • Bacteremic - longer; up to 28 days
  • Mycoplasma sp and Chlamydophilia sp
10-14 days
  • Legionella sp
14-21 days; 10 days (azalides)
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Respirology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
01 Jun 2016
Fluticasone furoate is superior to mometasone nasal spray in improving several perceived sensory attributes of allergic rhinitis patients, based on a multicentre, randomised, crossover, prospective study.
24 May 2018
In children and adolescents with cystic fibrosis (CF), synbiotic supplementation appears to be effective at reducing proinflammatory markers such as interleukin (IL)-6 and -8, and nitric oxide metabolites (NOx), a recent study has found.
15 Apr 2018
The use of transbronchial lung biopsy (TBLB) appears to be safe and effective for the pathological diagnosis of lymphangioleiomyomatosis (LAM), suggests a recent study.